1600-6143/asset/olbannerleft.gif?v=1&s=c46a3f174bfd9c6eb548cc809401524372c32e90)
1600-6143/asset/olbannerright.gif?v=1&s=9fc9790fa8ad5ef85aeaf408bf0d3d969d2fc012)
A Retrospective Analysis of Ezetimibe Treatment in Renal Transplant Recipients
Article first published online: 27 FEB 2006
DOI: 10.1111/j.1600-6143.2006.01263.x
Additional Information
How to Cite
Buchanan, C., Smith, L., Corbett, J., Nelson, E. and Shihab, F. (2006), A Retrospective Analysis of Ezetimibe Treatment in Renal Transplant Recipients. American Journal of Transplantation, 6: 770–774. doi: 10.1111/j.1600-6143.2006.01263.x
Publication History
- Issue published online: 27 FEB 2006
- Article first published online: 27 FEB 2006
- Received 3 June 2005, revised and accepted for publication 29 December 2005
- Abstract
- Article
- References
- Cited By
Keywords:
- Dyslipidemia;
- hyperlipidemia;
- kidney transplantation
A retrospective review was conducted to determine the safety and efficacy of ezetimibe as a treatment option for renal transplant recipients. We evaluated the medical records of 34 adult renal transplant recipients receiving ezetimibe as monotherapy or combination therapy. Fasting lipid profiles were obtained at baseline and at 1–6 months post-ezetimibe initiation. Twenty patients received cyclosporine, 12 patients received tacrolimus, 1 patient received either sirolimus or no calcineurin therapy at the time of ezetimibe initiation. Monotherapy was started in 8 patients, who had all previously failed statins, and combination therapy was utilized in 26 patients. Monotherapy or combination therapy resulted in a mean reduction in total cholesterol of 23.3%, triglycerides 40.2%, low-density lipoproteins 16.8% and high-density lipoproteins 4.8% after 3.1 months of therapy. Ezetimibe as combination or monotherapy is a safe and effective treatment option for dyslipidemia in renal transplant recipients without changes in calcineurin inhibitor levels or renal function.